Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

Baseline characteristics of patients enrolled in EXCELS: a cohort study

(2010) Aidan A. Long et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

After 6 years with Xolair; a 3-year withdrawal follow-up

(2009) A. Nopp et al.   ALLERGY

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

(2009) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

(2009) Raymond G. Slavin et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

(2009) Bob Lanier et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reduction of the Total IgE Level by Omalizumab in Children and Adolescents

(2009) Raymond G. Slavin et al.   JOURNAL OF ASTHMA

Reduction of the Total IgE Level by Omalizumab in Children and Adolescents

(2008) J. O. Steiss et al.   JOURNAL OF ASTHMA